What is claimed is:

1. A chimeric clotting factor which comprises i) a clotting factor selected from the group consisting of FVII, FIX and FX and ii) a targeting moiety which binds to platelets and, optionally, iii) a spacer moiety between the clotting factor and the targeting moiety.

2. The chimeric clotting factor of claim 1, which comprises a structure represented by the formula A B C, wherein A is the clotting factor; wherein B is a spacer moiety; and wherein C is at least one targeting moiety which binds to platelets.

3. The chimeric clotting factor of claim 2, which comprises a structure from amino terminus to carboxy terminus represented by a formula selected from the group consisting of: A B C; C B A.

4. The chimeric clotting factor of claim 1, wherein said chimeric clotting factor exhibits increased generation of thrombin in the presence of platelets as compared to an appropriate control lacking the at least one targeting moiety.

5. The chimeric clotting factor of claim 1, further comprising a scaffold moiety and, optionally, a second spacer moiety.

6. The chimeric clotting factor of claim 5, further comprising D and E, wherein D is a spacer moiety; and E is a scaffold moiety and wherein the chimeric clotting factor comprises a structure from amino terminus to carboxy terminus represented by a formula selected from the group consisting of: A B C D E; A D E B C; E D A B C; C B A D E; E D C B A; and C B E D A.

7. The chimeric clotting factor of claim 6, wherein E is a dimeric Fc region comprising a first Fc moiety, F1 and a second Fc moiety, F2.

8. The chimeric clotting factor of claim 7, wherein the clotting factor is expressed as a polypeptide comprising a cleavable scFc (cscFc) linker interposed between two Fc moieties, wherein the cscFc linker is adjacent to at least one enzymatic cleavage site which results in cleavage of the cscFc polypeptide linker.

9. The chimeric clotting factor of claim 8, wherein the cscFc linker is adjacent to at least one enzymatic cleavage site which results in cleavage of the cscFc linker.

10. The chimeric clotting factor of claim 9, wherein the at least one enzymatic cleavage site is an intracellular processing site.

11. The chimeric clotting factor of claim 9, wherein the polypeptide linker is flanked by two enzymatic cleavage sites which are recognized by the same or by different enzymes.

12. The chimeric clotting factor of claim 9, wherein the polypeptide linker has a length of about 10 to about 50 amino acids.

13. The chimeric clotting factor of claim 9, wherein the polypeptide linker has a length of about 20 to about 30 amino acids.

14. The chimeric clotting factor of claim 9, wherein the polypeptide linker comprises a gly/ser peptide.

15. The chimeric clotting factor of claim 14, wherein the gly/ser peptide is of the formula $(Gly_4Ser)n$, or $Ser(Gly_4Ser)n$ wherein n is a positive integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

16. The chimeric clotting factor of claim 15, wherein the $(Gly_4\ Ser)n$ linker is selected from the group consisting of $(Gly_4\ Ser)6$, $Ser(Gly_4\ Ser)6$, $(Gly_4\ Ser)4$ and $Ser(Gly_4\ Ser)4$.

17. The chimeric clotting factor of claim 8, wherein the clotting factor comprises two polypeptide chains.

18. The chimeric clotting factor of claim 7, wherein the chimeric clotting factor has a struture selected from the group consisting of: A linked to F1 via a spacer moiety and C linked to F2; A linked to F1 via a spacer moiety and C linked to F2 via a spacer moiety; A linked to F1 and C is linked to F2 via a spacer moiety; A linked to F1 via a spacer moiety and C is linked to F2 via a spacer moiety.

19. The chimeric clotting factor of claim 18, which comprises two polypeptides wherein the first polypeptide comprises the moieties A B F1; A B F1; A B F1, A B F1 D C and the second polypeptide comprises the moieties C F2; C D F2;:F2 D C, F2 D C, wherein the two polypeptide chains form an Fc region.

20. The chimeric clotting factor of claim 7, wherein the targeting moiety is fused to at least one of the polypeptide chains of the Fc region.

21. The chimeric clotting factor of claim 7, wherein the targeting moiety is fused to at least one of F1 and F2 directly.

22. The chimeric clotting factor of claim 7, wherein the targeting moiety is fused to at least one of F1 and F2 via a spacer moiety.

23. The chimeric clotting factor of claim 7, wherein the targeting moiety is fused to at least one of F1 and F2 via a cleavable linker.

24. The chimeric clotting factor of claim 1, wherein the targeting moiety is selected from the group consisting of: an antibody molecule, an antigen binding fragment of an antibody molecule, an scFv molecule, a receptor binding portion of a receptor, a peptide.

25. The chimeric clotting factor of claim 1, 2, 5 or 7 wherein the targeting moiety binds to resting platelets.

26. The chimeric clotting factor of 1, 2, 5 or 7 wherein the targeting moiety selectively binds to activated platelets.

27. The chimeric clotting factor of claim 25, wherein the targeting moiety selectively binds to a target selected from the group consisting of: GPIba, GPVI, and the nonactive form of GPIIb/IIIa.

28. The chimeric clotting factor of claim 26, wherein the targeting moiety selectively binds to a target selected from the group consisting of: the active form of GPIIb/IIIa, P selectin, GMP-33, LAMP-1, LAMP-2, CD40L, and LOX-1.

29. The chimeric clotting factor of claim 25, wherein the targeting moiety binds to the GPIb complex

30. The chimeric clotting factor of claim 25 wherein the targeting moiety is a peptide selected from the group consisting of: PS4, OS1, and OS2.

31. The chimeric clotting factor of claim 25, wherein the targeting moiety comprises an antibody variable regions from an antibody selected from the group consisting of: SCE5, MB9, and AP3.

32. The chimeric clotting factor of claim 1, 2, 5, or 7 wherein the clotting factor is Factor VII.

33. The chimeric clotting factor of claim 1, 2, 5, or 7, wherein the clotting factor is a high specific activity variant of Factor VII.

34. The chimeric clotting factor of claim 1, 2, 5, or 7 wherein the clotting factor is Factor IX.

35. The chimeric clotting factor of claim 1, 2, 5, or 7 wherein the clotting factor is a high specific activity variant of Factor IX.

36. The chimeric clotting factor of claim 1, 2, 5, or 7 wherein the clotting factor is Factor X.

37. The chimeric clotting factor of claim 1, 3, 4, or 5 wherein the clotting factor is a high specific activity variant of Factor X.

38. The chimeric clotting factor of claim 8, wherein the clotting factor is secreted by a cell in active form.

39. The chimeric clotting factor of claim 1, wherein the clotting factor is activated in vivo.

40. The chimeric clotting factor of claim 39 wherein the chimeric clotting factor comprises a heterologous enzymatic cleavage site not naturally present in the clotting factor.

41. The chimeric clotting factor of claim 40, wherein enzymatic cleavage site is genetically fused to the amino terminus of the heavy chain moiety of the clotting factor.

42. The chimeric clotting factor of claim 5, wherein the scaffold moiety is a protein molecule which increases the hydrodynamic radius of the chimeric clotting factor.

43. The chimeric clotting factor of claim 42, wherein the scaffold moiety, if present, is selected from the group consisting of albumin and XTEN®

44. A polypeptide comprising FVII, which FVII comprises a heterologous enzymatic cleavage site activatable by a component of the clotting cascade.

45. The polypeptide of claim 44, wherein the polypeptide comprises a scaffold moiety and, optionally, a spacer moiety.

46. The chimeric clotting factor of claim 45, wherein the scaffold moiety is a dimeric Fc region comprising a first Fc moiety, F1 and a second Fc moiety, F2.

47. The chimeric clotting factor of claim 44, wherein the clotting factor comprises two polypeptide chains.

48. The chimeric clotting factor of claim 44, wherein the chimeric clotting factor has a struture selected from the group consisting of: the clotting factor linked to the first Fc moiety via a spacer moiety; the clotting factor linked to the linked to the second Fc moiety via a spacer moiety; the clotting factor is directly linked to F1; and the clotting factor is directly linked to F2.

49. The chimeric clotting factor of claim 47, further comprising a targeting moiety, C.

50. The chimeric clotting factor of claim 47, wherein the chimeric clotting factor is synthesized as a single polypeptide chain comprising a cscFc linker.

51. The chimeric clotting factor of claim 49, wherein the cscFc linker is adjacent to at least one enzymatic cleavage site which results in cleavage of the linker.

52. The chimeric clotting factor of claim 50, wherein the at least one enzymatic cleavage site is an intracellular processing site.

53. The chimeric clotting factor of claim 50, wherein the cscFc linker is flanked by two enzymatic cleavage sites which are recognized by the same or by different enzymes.

54. The chimeric clotting factor of claim 49, wherein the cscFc linker has a length of about 10 to about 50 amino acids.

55. The chimeric clotting factor of claim 49, wherein the cscFc linker has a length of about 20 to about 30 amino acids.

56. The chimeric clotting factor of claim 49, wherein the cscFc linker comprises a gly/ser peptide.

57. The chimeric clotting factor of claim 56, wherein the gly/ser peptide is of the formula $(Gly_4Ser)n$, or $Ser(Gly_4Ser)n$ wherein n is a positive integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

58. The chimeric clotting factor of claim 56, wherein the $(Gly_4\ Ser)n$ linker is selected from the group consisting of $(Gly_4\ Ser)6$, $Ser(Gly_4\ Ser)6$, $(Gly_4\ Ser)4$ and $Ser(Gly_4\ Ser)4$.

59. The chimeric clotting factor of claim 45, wherein the clotting factor is a high specific activity variant of Factor VII.

60. The chimeric clotting factor of claim 44 wherein the heterologous enzymatic cleavage site not naturally present in the clotting factor is cleaved at the site of clot formation.

61. The chimeric clotting factor of claim 44, wherein the cleavage site is selected from the group consisting of: a factor XIa cleaveage site, a factor Xa cleavage site, and a thrombin cleavage site.

62. The chimeric clotting factor of claim 59, wherein enzymatic cleavage site is genetically fused to the amino terminus of the heavy chain moiety of the clotting factor.

63. The chimeric clotting factor of claim 48 wherein the targeting moiety binds to resting platelets.

64. The chimeric clotting factor of 48, wherein the targeting moiety selectively binds to activated platelets.

65. The chimeric clotting factor of claim 63, wherein the targeting moiety selectively binds to a target selected from the group consisting of: GPIba, GPVI, and the nonactive form of GPIIb/IIIa.

66. The chimeric clotting factor of claim 64, wherein the targeting moiety selectively binds to a target selected from the group consisting of: the active form of GPIIb/IIIa, P selectin, GMP-33, LAMP-1, LAMP-2, CD40L, and LOX-1.

67. The chimeric clotting factor of claim 64, wherein the scaffold moiety is a protein molecule which increases the hydrodynamic radius of the chimeric clotting factor.

68. The chimeric clotting factor of claim 67, wherein the scaffold moiety, if present, is selected from the group consisting of albumin and XTEN®

69. The chimeric clotting factor of claim 44, which comprises a linear sequence of moieties from amino terminus to carboxy terminus selected from the group consisting of: A B C; C B A; A B C D E; A D E B C, E D A B C, C B A D E, E D C B A, C B E D A, wherein A an activatable clotting factor, B is absent or is a linker, C is a targeting moiety, D is absent or is a linker, and E is a scaffold moiety.

70. The chimeric clotting factor of claim 44, wherein the clotting factor comprises a light and heavy chain of a clotting factor and each of the light and heavy chains are expressed as separate polypeptide chains.

71. A nucleic acid molecule encoding a chimeric clotting factor of any one of claims 1, 2, 5, 7, 44, 45, 45 and 58.

72. The nucleic acid molecule of claim 71, wherein the nucleic acid molecule is present in a vector.

73. The vector of claim 72 wherein the vector further comprises a nucleotide sequence encoding an enzyme which cleaves at least one of the enzymatic cleavage sites.

74. A host cell comprising the expression vector of claim 72.

75. A host cell comprising the expression vector of claim 72, wherein the host cell expresses an enzyme capable of intracellular processing.

76. The host cell of claim 75, wherein the enzyme is endogenous to the cell.

77. The host cell of claim 75, wherein the enzyme is heterologous to the cell.

78. A method for producing a chimeric clotting factor comprising culturing the host cell of claim 76 or 77 in culture and recovering the chimeric clotting factor from the medium.

79. A processed, heterodimeric polypeptide comprising two polypeptide chains, wherein said processed, heterodimeric polypeptide is made by expressing the vector of claim 78 in a cell cultured in cell culture medium and isolating the mature, heterodimeric polypeptide from the culture medium.

80. A composition comprising a chimeric clotting factor of any one of claims 1, 2, 5, 7, 44, 45, 48 and 58 and a pharmaceutically acceptable carrier.

81. A composition comprising the nucleic acid molecule of claim 71 and a pharmaceutically acceptable carrier.

82. A method for improving hemostasis in a subject, comprising administering the composition of claim 80 or 81.

What is claimed is:

1. An invention not claimed in any divisional application.